Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vioxx litigation setbacks

Executive Summary

Atlantic City, N.J. state court judge sets aside a November verdict in favor of Merck and ordered a new trial for early next year, drug maker says Aug. 17. Decision comes after the New England Journal of Medicine asked Merck to submit a correction restating results of its Vioxx Gastrointestinal Outcomes Research (VIGOR) in a December Expression of Concern (1"The Pink Sheet" Dec. 12, 2005, p. 9). Jury in Humeston v. Merck had cleared the firm of allegations it failed to properly warn patients of risks associated with the use of rofecoxib. Company says it is currently mulling its legal options, which could include interlocutory appeal. Separately, a New Orleans jury awards $51 mil. in damages to the plaintiff in the second Vioxx federal lawsuit, a verdict the firm says it will challenge...

You may also be interested in...

Merck Will Need VIGOR To Defend Vioxx Data Following NEJM Claims

The New England Journal of Medicine has asked the authors of a major Vioxx study to submit a correction restating results after the journal concluded that cardiovascular events were misrepresented in the study manuscript and that Merck had known about additional events prior to the trial's publication

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts